Eli Lilly has achieved an extraordinary medical breakthrough with ZEPBOUND (tirzepatide), establishing new therapeutic standards within sleep disorder healthcare delivery. The landmark FDA approves ZEPBOUND for obstructive sleep apnea approval in December 2024 introduces the first medication specifically formulated to combat this widespread sleep-related respiratory disorder. This regulatory...
English
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt